Paraprotéines et atteintes réenales

Article Article scientifique Article Paraprotéines et atteintes réenales fre Paraproteinemia and renal diseases 2010 author Grandjean Anne Pascale 512222 author Dettwiler Sarah 61903 author Saudan Patrick 41867 460-466 20344997 1660-9379 Paraproteinaemia is frequent in the population above 50 years of age. It is commonly associated in patients with multiple myeloma with diverse renal involvements, such as cast nephropathy, light chain deposition disease, amyloidosis and Fanconi syndrome. A rapid diagnosis is necessary to implement a specific and aggressive treatment in order to prevent development of end-stage renal disease. Plasma exchanges or daily dialysis with high-cut off filter associated with chemotherapy may decrease the plasmatic concentration and production of monoclonal light chains. Bortezomib, thalidomide and lenalidomide are promising therapeutic agents, whose effects in patients with myeloma-associated renal diseases should be more thoroughly studied. Autologous hematopoietic cell transplantation remains the standard of care treatment for eligible patients. Biopsy Humans Kidney/pathology Kidney Diseases/*complications/therapy Paraproteinemias/*complications/diagnosis/therapy Prognosis Dewey 616 56 Département de médecine 221 false Revue médicale suisse 6 238 Faculté de médecine / Section de médecine clinique / Département de médecine

Title	Published in	Access level	OA Policy	Year	Views	Downloads

Paraprotéines et atteintes réenales	Revue médicale suisse			2010	516	0

Archive ouverte UNIGE

Grandjean, Anne Pascale